

# CARDIOVASCULAR RISK REDUCTION IN T2DM: Applying the Trial Data to Clinical Practice

• Robert H. Eckel MD (Chair)  
• Deepak L. Bhatt MD MPH  
• Lawrence Blonde MD  
• Harold Bays MD

Jointly provided by Cardiometabolic Health Congress and Global Education Group

## 1 WHY DOES IT MATTER

### THE BIG PICTURE




### GAP



### CVOTS: A SURPRISING SOLUTION?



### BUT ANOTHER GAP...




## 2 WHAT CLINICIANS NEED TO KNOW




## 3 THE INTERVENTION


### MULTI-MODAL INFOGRAPHIC ACTIVITIES: DIDACTIC LECTURES, CASE-BASED PRESENTATIONS




## 4 THE EDUCATION ENGAGED THE APPROPRIATE AUDIENCE




## 5 RESULTS ACROSS LEARNING OBJECTIVES



## 6 PRACTICE CHANGES



## 7 WHAT IT MEANS



## 8 ONGOING EDUCATIONAL NEEDS



## REFERENCES

• Das, Sandeep R., et al. "2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways." *Journal of the American College of Cardiology* 72.24 (2018): 3200-3223.

• Hinnen, Deborah, and David F. Kugler. "Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials." *Diabetes, metabolic syndrome and obesity: targets and therapy* 12 (2019): 447.

The activities in this program were jointly provided by Cardiometabolic Health Congress and Global Education Group.

Supported by educational grants from AstraZeneca and Novo Nordisk.

Scan the QR code to access a PDF of this poster online and supplementary program and outcomes measurement information.

